The clinical trial conducted by Fred Hutchinson Cancer Center investigates the efficacy of ondansetron in reducing DMSO-related nausea and vomiting in patients undergoing autologous peripheral blood stem cell transplantation. Given the high incidence of nausea and vomiting associated with stem cell transplants, successful outcomes could position ondansetron as a standard supportive care option in this setting, potentially increasing its market share in oncology supportive care. The competitive landscape includes other antiemetics, but ondansetron's established safety profile and FDA approval may provide a competitive advantage. Diligence should focus on market access strategies and potential reimbursement pathways, as well as ongoing clinical data to support its use in this specific patient population.